^
    over3years
    Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer. (PubMed, BMC Cancer)
    Genetically and clinically annotated HNSCC PDXs could be useful preclinical tools for evaluating biomarkers, therapeutic targets, and new drug discovery.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CCND1 (Cyclin D1)
    |
    TP53 mutation • PIK3CA mutation • PIK3CA H1047R • PIK3CA amplification • HRAS mutation • CCND1 amplification • NRAS G12 • HRAS G12D
    4years
    [VIRTUAL] SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study. (ASCO 2020)
    Pharmacodynamic analyses support the antitumor and immune effects of sitravatinib and nivolumab in OCC. Immune pathological response assessment and transcriptomics are on-going. Research Funding: Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Pharmaceutical/Biotech Company
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • AXL (AXL Receptor Tyrosine Kinase) • VEGFA (Vascular endothelial growth factor A) • MERTK (MER Proto-Oncogene, Tyrosine Kinase)
    |
    HRAS mutation • BLM mutation • HRAS G12D
    |
    Opdivo (nivolumab) • sitravatinib (MGCD516)